Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance
Nephron · 13.06.2026 · 1-8
DOI: 10.1159/000553058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron, online erschienen am 13.06.2026. Verfasst von Gerard Gurumurthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Kidney Diseases, Paraproteinemias. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Monoclonal gammopathy of renal significance (MGRS) is a rare group of renal disorders caused by monoclonal immunoglobulins from non-malignant B-cell or plasma cell clones, with distinct amyloid (MGRS-A) and non-amyloid (MGRS-NA) subtypes. Although these are often grouped together, whether they share similar clinical phenotypes and outcomes is uncertain. We therefore examined similarities and differences between these subtypes in a contemporary real-world cohort.
Methods
We performed a single-centre retrospective evaluation of 17 biopsy-confirmed MGRS patients (10 MGRS-A, 7 MGRS-NA). Baseline parameters, treatment exposure, renal and haematologic responses, survival, and relapse were analysed descriptively with exploratory subgroup comparisons.
Results
MGRS-NA patients presented with significantly worse baseline renal function (median estimated glomerular filtration rate 18.0 mL/min/1.73 m2 vs. 49.0 mL/min/1.73 m2 in MGRS-A, p < 0.05) and progressed faster to dialysis (p < 0.01). Haematologic responses (≥VGPR) were achieved in 57.1% of MGRS-NA and 50% of MGRS-A patients, but these did not significantly correlate with renal improvement. Survival was similar between groups, with deaths in 28.6% of MGRS-NA and 20% of MGRS-A. Relapse occurred in 47.1% of patients, with median times of 51 months in MGRS-NA and 69 months in MGRS-A. Treatment, primarily bortezomib-based chemotherapy, was associated with toxicities (94.1%), yet renal responses remained limited.
Conclusion
The findings highlight the poor prognosis and rapid renal decline in MGRS-NA. We highlight the need for early diagnosis and an integrated renal-haematologic service to improve outcomes in this rare population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The University of Manchester, Manchester, UK.
- Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
- Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK, durga.kanigicherla@mft.nhs.uk.
- Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, UK, durga.kanigicherla@mft.nhs.uk.
Zitieren
APA
Gurumurthy, G., Fielding, J., Crea, P., & Kanigicherla, D. A. K. (2026). Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance. Nephron, 1-8. https://doi.org/10.1159/000553058
Vancouver
Gurumurthy G, Fielding J, Crea P, Kanigicherla DAK. Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance. Nephron. 2026:1-8. doi:10.1159/000553058
BibTeX
@article{Gurumurthy2026,
author = {Gurumurthy, Gerard and Fielding, Jenna and Crea, Philip and Kanigicherla, Durga A K},
title = {Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance},
journal = {Nephron},
year = {2026},
pages = {1--8},
doi = {10.1159/000553058}
}
EUVIMED